CNBC: Investing

JUNE 9, 2025

Cardinal Health Josh — All three major Pharmaceutical Wholesalers made the list - McKesson (MCK) , Cencora (COR) and Cardinal Health (CAH) , only Cardinal looks good technically right now: CAH held its 50-day on a weekly closing basis during the April bloodbath, I'd use that area as a stop and update it each week.

Healthcare 59

Healthcare Stock S&P Pharmaceutical 59

M&A Leadership Council

AUGUST 15, 2022

A sell-off, which is by far the most common type of divestiture (and the type usually referred to as such), is the sale of one or more company units to another company – for example, when BF Goodrich Corporation sold its JcAIR Test Systems business to Aeroflex Incorporated in 2005. What is a sell-off? . What is a spin-off?

Mergers and Acquisitions 40

Mergers and Acquisitions IPO M&A Initial Public Offering 40

Cooley M&A

JANUARY 25, 2023

But it wasn’t all carve outs and concerned investors – even with the headwinds in the industry and beyond, there were still several traditional public M&A deals involving biotechnology or medical device companies, as large pharmaceutical companies continued to have cash to deploy for acquisitions. Let’s dig in.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Collaboration 40

Cooley M&A

JANUARY 23, 2024

While the year saw an overall decline in M&A activity (down 17% from 2022) , total pharmaceuticals and life sciences deal value in 2023 increased by approximately 50% compared to 2022. Looming patent cliffs By 2030, more than 190 drugs will lose patent exclusivity , including 69 blockbuster drugs, putting at risk $236 billion in sales.

M&A 52

M&A Mergers and Acquisitions Pharmaceutical Acquisitions 52

Mergers and Inquisitions

NOVEMBER 1, 2023

At the time of the deal, it was expected to grow sales at 3-5%: Remember that PE deals do not require “growth.” Advanced Financial Modeling : There’s a case study on Jazz Pharmaceuticals if you’re more interested in that vertical. What about when the IPO market is shut down and exits look uncertain? Specifically, in the U.S.,

Private Equity 59

Private Equity Healthcare Equities Middle Market 59

Cooley M&A

JANUARY 22, 2021

The second half of the year witnessed a rebound spurred by several multibillion-dollar deals, including Gilead’s acquisition of Immunomedics for nearly $21 billion and AstraZeneca’s proposed acquisition of Alexion Pharmaceuticals for $39 billion. While deal value was down for the year, deal volume was relatively stable (down only 2.0%

M&A 40

M&A Mergers and Acquisitions Collaboration Mergers 40

Cooley M&A

JANUARY 20, 2022

1] Major all-cash acquisitions have followed, such as Arena Pharmaceutical’s agreement to sell to Pfizer for $6.7 Midsize pharmaceutical buyers pursuing opportunistic acquisition strategies, with robust capital markets and high valuations having limited the pool of attractive assets available in recent years. closing friction.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Mergers 40